Opana ER Maker to Stop Marketing Drug as Crush-Resistant Under NY Settlement

The maker of the long-acting painkiller Opana ER has agreed to stop marketing the drug as crush-resistant, under a settlement with New York State. The company also agreed to accurately describe the risk of addiction to the drug, Reuters reports.

Under the agreement with New York State, Endo Health Solutions and Endo Pharmaceuticals will also pay a $200,000 penalty, according to New York State Attorney General Eric T. Schneiderman. He said the company’s own studies found Opana ER could be crushed and ground. “This may have bolstered Opana ER sales, but provided a false sense of security to health care providers and their patients,” according to a statement by Schneiderman’s office.

The Attorney General also found that Endo improperly instructed its sales representatives to “diminish and distort risks associated with Opana ER, including serious dangers involving addiction,” Schneiderman’s office stated.

Full story of Opana ER and marketing at drugfree.org

Published by

Will Savage

Quantum Units Continuing Education provides online CEU training's to licensed professional mental health therapists, counselors, social workers and nurses. Our blog provides updates in the field of news and research related to mental health and substance abuse treatment.